Tags : Dr. Kimberly Smith

Viewpoints

ViewPoints Interview: ViiV Healthcare’s Dr. Kimberly Smith Shares Insight on

In an interview with PharmaShots, Dr. Kimberly Smith, Head of Research & Development, ViiV Healthcare shed light on the FDA’s approval and the 3yrs. data of Dovato. Shots: Dovato (dolutegravir/lamivudine) is the first complete, once-daily, single-tablet, 2DR for the treatment of HIV-1 infection in both treatment-naïve and virologically suppressed adults In Aug 2020, the FDA […]Read More